Patents by Inventor Reema K. Thalji

Reema K. Thalji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10174053
    Abstract: The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 8, 2019
    Assignees: Glaxo Group Limited, Shionogi and Co., Ltd.
    Inventors: Toshiaki Aoki, Hiroki Kusano, Xiangmin Liao, Neil David Pearson, Israil Pendrak, Jun Sato, Reema K. Thalji, Kenji Yamawaki, Katsuki Yokoo
  • Publication number: 20170281532
    Abstract: The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 5, 2017
    Inventors: Toshiaki AOKI, Hiroki KUSANO, Xiangmin LIAO, Neil David PEARSON, Israil PENDRAK, Jun SATO, Reema K. THALJI, Kenji YAMAWAKI, Katsuki YOKOO
  • Patent number: 8212032
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: July 3, 2012
    Assignee: GlaxoSmithKline LLC.
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, Jr.
  • Patent number: 8173805
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: May 8, 2012
    Assignee: GlaxoSmithKline, LLC
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, Jr.
  • Patent number: 8008483
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: August 30, 2011
    Assignee: Glaxosmithkline, LLC
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, Jr.
  • Publication number: 20100249137
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof. The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: April 9, 2010
    Publication date: September 30, 2010
    Inventors: Yun DING, Reema K. Thalji, Joseph P. Marino, JR.
  • Publication number: 20100210656
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 19, 2010
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, JR.
  • Publication number: 20100210628
    Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: October 10, 2008
    Publication date: August 19, 2010
    Inventors: Yun Ding, Reema K. Thalji, Joseph P. Marino, JR.